The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1273
November 5, 2007
View Complete Issue         Table of Contents 2019 
A Once-Yearly IV Bisphosphonate for Osteoporosis
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
A Once-Yearly IV Bisphosphonate for Osteoporosis
November 5, 2007 (Issue: 1273)
Zoledronic acid (Reclast - Novartis) is the first bisphosphonate approved by the FDA for once-yearly intravenous (IV) treatment of osteoporosis in postmenopausal women. Reclast is also approved for treatment of Paget's disease. Another IV formulation...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: A Once-Yearly IV Bisphosphonate for Osteoporosis
Article code: 1273a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.